EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Salidroside: A Promising Agent in Bone Metabolism Modulation

Piotr Wojdasiewicz iD, Stanisław Brodacki, Ewa Cieślicka, Paweł Turczyn, Łukasz A Poniatowski, Weronika Ławniczak, Mieszko Olczak iD, Elżbieta U Stolarczyk iD, Edyta Wróbel, Agnieszka Mikulska iD, Anna Lach-Gruba, Beata Żuk und 2 weitere

Nutrients · 2024

DOI: 10.3390/nu16152387 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nutrients, 2024. Verfasst von Piotr Wojdasiewicz und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biophysics, Physiology and Pathophysiology, Faculty of Health Sciences, Medical University of Warsaw, Chałubińskiego 5, 02-004 Warsaw, …. Hauptthemen laut MEDLINE: Glucosides, Phenols, Bone and Bones, Osteogenesis. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rhodiola rosea, a long-lived herbaceous plant from the Crassulaceae group, contains the active compound salidroside, recognized as an adaptogen with significant therapeutic potential for bone metabolism. Salidroside promotes osteoblast proliferation and differentiation by activating critical signaling pathways, including bone morphogenetic protein-2 and adenosine monophosphate-activated protein kinase, essential for bone formation and growth. It enhances osteogenic activity by increasing alkaline phosphatase activity and mineralization markers, while upregulating key regulatory proteins including runt-related transcription factor 2 and osterix. Additionally, salidroside facilitates angiogenesis via the hypoxia-inducible factor 1-alpha and vascular endothelial growth factor pathway, crucial for coupling bone development with vascular support. Its antioxidant properties offer protection against bone loss by reducing oxidative stress and promoting osteogenic differentiation through the nuclear factor erythroid 2-related factor 2 pathway. Salidroside has the capability to counteract the negative effects of glucocorticoids on bone cells and prevents steroid-induced osteonecrosis. Additionally, it exhibits multifaceted anti-inflammatory actions, notably through the inhibition of tumor necrosis factor-alpha and interleukin-6 expression, while enhancing the expression of interleukin-10. This publication presents a comprehensive review of the literature on the impact of salidroside on various aspects of bone tissue metabolism, emphasizing its potential role in the prevention and treatment of osteoporosis and other diseases affecting bone physiology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucosidesPhenolsBone and BonesOsteogenesisOsteoporosisOsteoblastsHumansAnimalsRhodiolaSignal TransductionAntioxidantsCell DifferentiationAnti-Inflammatory Agents

Stichwörter der Autor:innen

Rhodiola roseaadaptogensfracture healingosteoarthritisosteoporosissalidroside

Substanzen

rhodiolosideGlucosidesPhenolsAntioxidantsAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Department of Biophysics, Physiology and Pathophysiology, Faculty of Health Sciences, Medical University of Warsaw, Chałubińskiego 5, 02-004 Warsaw, Poland.
  • Department of Rehabilitation, St. Anna's Trauma Surgery Hospital, Mazovian Rehabilitation Center-STOCER, Barska 16/20, 02-315 Warsaw, Poland.
  • Department of Early Arthritis, Eleonora Reicher National Institute of Geriatrics, Rheumatology and Rehabilitation, Spartańska 1, 02-637 Warsaw, Poland.
  • Department of Neurosurgery, Dietrich-Bonhoeffer-Klinikum, Salvador-Allende-Straße 30, 17036 Neubrandenburg, Germany.
  • Health Department, Institute of Health Holispace, ul. Św. Wincentego 93/5, 03-291 Warsaw, Poland.
  • Department of Forensic Medicine, Center for Biostructure Research, Medical University of Warsaw, Oczki 1, 02-007 Warsaw, Poland.

ORCID-Profile: Piotr Wojdasiewicz, Mieszko Olczak, Elżbieta U Stolarczyk, Agnieszka Mikulska, Dariusz Szukiewicz

Zitieren

APA

Wojdasiewicz, P., Brodacki, S., Cieślicka, E., Turczyn, P., Poniatowski, Ł. A., Ławniczak, W., Olczak, M., Stolarczyk, E. U., Wróbel, E., Mikulska, A., Lach-Gruba, A., Żuk, B., Romanowska-Próchnicka, K., & Szukiewicz, D. (2024). Salidroside: A Promising Agent in Bone Metabolism Modulation. Nutrients. https://doi.org/10.3390/nu16152387

Vancouver

Wojdasiewicz P, Brodacki S, Cieślicka E, Turczyn P, Poniatowski ŁA, Ławniczak W, et al. Salidroside: A Promising Agent in Bone Metabolism Modulation. Nutrients. 2024. doi:10.3390/nu16152387

BibTeX
@article{Wojdasiewicz2024,
  author = {Wojdasiewicz, Piotr and Brodacki, Stanisław and Cieślicka, Ewa and Turczyn, Paweł and Poniatowski, Łukasz A and Ławniczak, Weronika and Olczak, Mieszko and Stolarczyk, Elżbieta U and Wróbel, Edyta and Mikulska, Agnieszka and Lach-Gruba, Anna and Żuk, Beata and Romanowska-Próchnicka, Katarzyna and Szukiewicz, Dariusz},
  title = {Salidroside: A Promising Agent in Bone Metabolism Modulation},
  journal = {Nutrients},
  year = {2024},
  doi = {10.3390/nu16152387}
}
Kostenlos starten →